---
title: "ETEK: Net profit of 16.68 million yuan in the first half of 2025, a year-on-year decrease of 78.72%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/255154937.md"
description: "ETEK announced that its operating revenue in the first half of 2025 was 351 million yuan, a year-on-year decrease of 14.62%. Net profit was 16.68 million yuan, a year-on-year decrease of 78.72%"
datetime: "2025-08-29T08:45:50.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/255154937.md)
  - [en](https://longbridge.com/en/news/255154937.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/255154937.md)
---

# ETEK: Net profit of 16.68 million yuan in the first half of 2025, a year-on-year decrease of 78.72%

ETEK announced that its operating revenue in the first half of 2025 was 351 million yuan, a year-on-year decrease of 14.62%. Net profit was 16.68 million yuan, a year-on-year decrease of 78.72%

### Related Stocks

- [688601.CN](https://longbridge.com/en/quote/688601.CN.md)

## Related News & Research

- [Flow Pharma U.S. Patent Application Allowed for Issuance Covering Broad-Spectrum Ebola Therapy](https://longbridge.com/en/news/287076761.md)
- [HSA warns public against consuming herbal remedy containing potent steroid](https://longbridge.com/en/news/287022845.md)
- [Xiaomi EV reportedly taps new battery suppliers for second brand to target EREV market](https://longbridge.com/en/news/286843996.md)
- [Pop star Wang Leehom swaps Denza endorsement fee for BYD stock](https://longbridge.com/en/news/286844734.md)
- [20:00 ETAccro Bioscience Announces $50 Million Series C Financing Led by OrbiMed to Advance Clinical Pipeline for Immune Mediated Diseases](https://longbridge.com/en/news/286830151.md)